Jade Biosciences (JBIO) EBITDA (2020 - 2026)

Jade Biosciences has reported EBITDA for 7 years, with the latest figure at -$40.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 7.0% year-over-year to -$40.8 million; the trailing twelve-month figure through Mar 2026 stood at -$130.0 million (down 26.65% YoY), and the FY2025 full-year result was -$127.3 million, down 82.46% from the prior year.
• EBITDA for Q1 2026 stood at -$40.8 million, down from -$31.8 million in the prior quarter.
• The five-year high for EBITDA was -$590000.0 in Q2 2024, with the low at -$47.0 million in Q4 2024.
• Historically, EBITDA has averaged -$22.5 million across 5 years, with a median of -$19.6 million in 2023.
• Annual changes were most pronounced in 2024 — EBITDA jumped 96.9% — and 2025, when it tumbled 5350.51%.
• Jade Biosciences' EBITDA stood at -$14.7 million in 2022, then plunged by 35.58% to -$20.0 million in 2023, then sank by 135.45% to -$47.0 million in 2024, then surged by 32.24% to -$31.8 million in 2025, then dropped by 28.3% to -$40.8 million in 2026.
• The last three EBITDA figures came in at -$40.8 million (Q1 2026), -$31.8 million (Q4 2025), and -$25.1 million (Q3 2025), per Business Quant data.